FDA Approves Genentech's Lunsumio To Treat Relapsed Or Refractory Follicular Lymphoma

SOUTH SAN FRANCISCO (dpa-AFX) - Genentech, a member of the Roche Group (RHHBY), said that the U.S. Food and Drug Administration has approved Lunsumio (mosunetuzumab-axgb) for the treatment of adult

Related Keywords

United States , , Genentech , Drug Administration , Roche Group , More Such Health News , Approves , Lunsumio , Treat , Relapsed , Refractory , Follicular , Lymphoma ,